1) Why, on this night
1) Are there inherent biases in the sampling strategies employed in NARMS? If so, how can they be improved to ensure that the data and interpretation are scientifically sound given current resources?
2) Are there epidemiological and/or microbiological research studies that would better serve the goals of NARMS and the regulatory work of FDA?
3) Are current plans for data harmonization and reporting appropriate? If not, what are the top priorities for advancing harmonized reporting?
4) Are the current NARMS international activities adequate to address the worldwide spread of antimicrobial-resistant foodborne bacteria?
At some point (unfortunately, my internet access is spotty while in D.C.), I’ll let you know what happened.